MedPath

Intrathecal Morphine for pain management in patients undergoing major abdominal surgery: The optimal dose?

Conditions
The use of intrathecal morphine for post-operative pain relief following major abdominal surgery - the comparison of two doses (10 micrograms/kg and 20 micrograms/kg)medical condition = post-operative pain
Registration Number
EUCTR2004-005222-41-GB
Lead Sponsor
HCW NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
100
Inclusion Criteria

The teaching hospital in Coventry is a tertiary referral centre with 900 beds and serves a population of 500,000. The subjects of the study will be patients undergoing major abdominal surgery related to either the vascular system or gastro-intestinal tract. A total of 100 patients will be recruited into the trial. The age range will be 30 to 80 years with no exclusion related to gender. Bias will be controlled by including all patients of all surgeons involved with this type of surgery. This should ensure that patients are representative of the general population undergoing this type of surgery. Patients will be randomly allocated to one of two groups – 50 will receive 10 micrograms intrathecal morphine per kilogram body weight (to a maximum of 1mg) and 50 will receive 20 micrograms intrathecal morphine per kilogram body weight (to a maximum of 2mg). 100 envelopes (50 with 10 micrograms/kg and 50 with 20 micrograms/kg) will be used and the anaesthetist involved with the patient will select one sealed envelope randomly. The study should take between six and twelve months. Surgeons and anaesthetists involved in the trial will be given an information pack related to the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients excluded will be those who do not consent, those with clotting abnormalities, systemic infection, those with localised infection of the skin in the lumbar region and women who are pregnant.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath